Free Trial

Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $27.00 Price Target at Needham & Company LLC

Day One Biopharmaceuticals logo with Medical background

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) had its price objective lowered by equities researchers at Needham & Company LLC from $30.00 to $27.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Needham & Company LLC's price objective indicates a potential upside of 302.08% from the stock's current price.

A number of other research firms have also commented on DAWN. HC Wainwright restated a "buy" rating and issued a $36.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, April 3rd. JPMorgan Chase & Co. dropped their price target on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 5th. Bank of America decreased their price objective on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. The Goldman Sachs Group dropped their target price on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a report on Tuesday, March 25th. Finally, Wedbush reaffirmed an "outperform" rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Day One Biopharmaceuticals has an average rating of "Buy" and a consensus price target of $30.57.

Read Our Latest Analysis on Day One Biopharmaceuticals

Day One Biopharmaceuticals Stock Up 4.1%

NASDAQ:DAWN traded up $0.27 during mid-day trading on Wednesday, reaching $6.72. 601,745 shares of the stock were exchanged, compared to its average volume of 1,077,179. The stock has a market capitalization of $680.65 million, a P/E ratio of -6.50 and a beta of -1.24. Day One Biopharmaceuticals has a 1 year low of $6.26 and a 1 year high of $17.14. The company has a 50 day simple moving average of $7.70 and a 200-day simple moving average of $11.05.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.46) by $0.11. The business had revenue of $30.76 million for the quarter, compared to analysts' expectations of $30.28 million. As a group, research analysts predict that Day One Biopharmaceuticals will post -0.72 EPS for the current year.

Insider Activity

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares in the company, valued at approximately $1,531,059.40. The trade was a 8.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the sale, the general counsel now owns 39,602 shares in the company, valued at $473,639.92. This represents a 10.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,064 shares of company stock worth $251,925 over the last 90 days. 6.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DAWN. GF Fund Management CO. LTD. purchased a new position in Day One Biopharmaceuticals during the fourth quarter worth $27,000. R Squared Ltd purchased a new position in Day One Biopharmaceuticals in the 4th quarter valued at about $31,000. Pallas Capital Advisors LLC acquired a new stake in shares of Day One Biopharmaceuticals during the 1st quarter worth about $87,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Day One Biopharmaceuticals during the first quarter worth about $88,000. Finally, Exchange Traded Concepts LLC grew its holdings in shares of Day One Biopharmaceuticals by 19.6% during the first quarter. Exchange Traded Concepts LLC now owns 14,693 shares of the company's stock worth $117,000 after buying an additional 2,407 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

(Get Free Report)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

Read More

Analyst Recommendations for Day One Biopharmaceuticals (NASDAQ:DAWN)

Should You Invest $1,000 in Day One Biopharmaceuticals Right Now?

Before you consider Day One Biopharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.

While Day One Biopharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines